Loading page...

Romanian Business News - ACTMedia :: Services|About us|Contact|RSS RSS


Antibiotice posts H1 net profit worth 19.14 million RON, down by 14 pct


The Romanian medicine manufacturer Antibiotice Iasi has achieved a net profit of 19.14 million RON in the first six months, down 14 pct compared to the same period last year, when it recorded a net profit of 22.31 million RON, according to a company statement.

According to the source, sales revenues, i.e. revenues from the sale of pharmaceutical products to domestic and external partners, made in the first six months were 146.38 million RON, which represents 85 pct of the value obtained in the same period of 2019.

"We note that, in the context of the fall in the local pharmaceutical market, export businesses balanced revenues by increasing their share to 50 pct in the first half of 2020 (compared to 42 pct in 2019)," the company release says.

The Iasi-based company achieved total revenues of 182 million RON in the same period, compared to 206 million RON in the first half of 2019.

At the same time, operating revenues are worth 179 million RON, compared to 203 million RON in 2019.

"In the first six months of 2020, marked by the crisis of the novel coronavirus, the company honored contracts worth 73.8 million RON on the international market, managing an increase of 2 pct compared to the previous year, when exports registered the value of 72.7 million RON. Antibiotice responded to the requests of both traditional partners and those from international health systems, supporting them with medicines associated with the COVID-19 treatment, although the conditions were not the most favorable," the release adds. 

According to the company, export sales of finished medicines and of the active substance Nystatin managed to support the company's turnover in the first six months of the year, so that, during this period marked by the boomerang effects of the pandemic, exports accounted for 50 pct of the turnover of the first semester".